US Bancorp’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $101K | Sell |
377
-5
| -1% | -$1.17K | ﹤0.01% | 2449 |
|
|
2026
Q1 | $87.4K | Sell |
382
-1,214
| -76% | -$272K | ﹤0.01% | 2451 |
|
|
2025
Q4 | $340K | Sell |
1,596
-563
| -26% | -$116K | ﹤0.01% | 1748 |
|
|
2025
Q3 | $429K | Buy |
2,159
+1,849
| +596% | +$345K | ﹤0.01% | 1601 |
|
|
2025
Q2 | $53.5K | Sell |
310
-5
| -2% | -$814 | ﹤0.01% | 2750 |
|
|
2025
Q1 | $49.1K | Sell |
315
-46
| -13% | -$6.57K | ﹤0.01% | 2760 |
|
|
2024
Q4 | $49.7K | Buy |
361
+73
| +25% | +$9.6K | ﹤0.01% | 2742 |
|
|
2024
Q3 | $43K | Sell |
288
-22
| -7% | -$2.97K | ﹤0.01% | 2816 |
|
|
2024
Q2 | $42.3K | Sell |
310
-6
| -2% | -$816 | ﹤0.01% | 2755 |
|
|
2024
Q1 | $47.8K | Buy |
316
+32
| +11% | +$4.57K | ﹤0.01% | 2727 |
|
|
2023
Q4 | $35.8K | Buy |
284
+74
| +35% | +$7.38K | ﹤0.01% | 2832 |
|
|
2023
Q3 | $19.7K | Buy |
210
+48
| +30% | +$4.49K | ﹤0.01% | 2888 |
|
|
2023
Q2 | $14.5K | Sell |
162
-901
| -85% | -$78.4K | ﹤0.01% | 3124 |
|
|
2023
Q1 | $114K | Sell |
1,063
-145
| -12% | -$16.6K | ﹤0.01% | 2122 |
|
|
2022
Q4 | $148K | Sell |
1,208
-45
| -4% | -$5.22K | ﹤0.01% | 2021 |
|
|
2022
Q3 | $130K | Buy |
1,253
+283
| +29% | +$26.8K | ﹤0.01% | 2063 |
|
|
2022
Q2 | $90K | Buy |
970
+357
| +58% | +$33.6K | ﹤0.01% | 2290 |
|
|
2022
Q1 | $72K | Sell |
613
-142
| -19% | -$16.4K | ﹤0.01% | 2430 |
|
|
2021
Q4 | $101K | Sell |
755
-164
| -18% | -$24.4K | ﹤0.01% | 2295 |
|
|
2021
Q3 | $146K | Buy |
919
+166
| +22% | +$22.7K | ﹤0.01% | 2090 |
|
|
2021
Q2 | $99K | Sell |
753
-63
| -8% | -$8.39K | ﹤0.01% | 2311 |
|
|
2021
Q1 | $106K | Buy |
816
+153
| +23% | +$23.3K | ﹤0.01% | 2238 |
|
|
2020
Q4 | $111K | Buy |
663
+11
| +2% | +$1.82K | ﹤0.01% | 2157 |
|
|
2020
Q3 | $101K | Sell |
652
-351
| -35% | -$50.5K | ﹤0.01% | 2078 |
|
|
2020
Q2 | $148K | Buy |
1,003
+401
| +67% | +$55.1K | ﹤0.01% | 1911 |
|
|
2020
Q1 | $68K | Buy |
602
+217
| +56% | +$28.2K | ﹤0.01% | 2204 |
|
|
2019
Q4 | $53K | Buy |
385
+217
| +129% | +$24.1K | ﹤0.01% | 2451 |
|
|
2019
Q3 | $16K | Buy |
168
+21
| +14% | +$2.34K | ﹤0.01% | 2915 |
|
|
2019
Q2 | $17K | Buy |
147
+16
| +12% | +$1.92K | ﹤0.01% | 2933 |
|
|
2019
Q1 | $15K | Buy |
131
+55
| +72% | +$4.82K | ﹤0.01% | 2943 |
|
|
2018
Q4 | $5K | Hold |
76
| – | – | ﹤0.01% | 3192 |
|
|
2018
Q3 | $5K | Hold |
76
| – | – | ﹤0.01% | 3302 |
|
|
2018
Q2 | $5K | Hold |
76
| – | – | ﹤0.01% | 3300 |
|
|
2018
Q1 | $5K | Hold |
76
| – | – | ﹤0.01% | 3305 |
|
|
2017
Q4 | $3K | Hold |
76
| – | – | ﹤0.01% | 3400 |
|
|
2017
Q3 | $3K | Hold |
76
| – | – | ﹤0.01% | 3345 |
|
|
2017
Q2 | $2K | Hold |
76
| – | – | ﹤0.01% | 3376 |
|
|
2017
Q1 | $2K | Hold |
76
| – | – | ﹤0.01% | 3379 |
|
|
2016
Q4 | $2K | Buy |
+76
| New | +$1.52K | ﹤0.01% | 3368 |
|
Other funds holding ASND
RCM
ACA
JT
US Bancorp's ASND Position: Q2 2026 in Review
US Bancorp reduced its Ascendis Pharma A/S (ASND) stake by 1.3% in Q2 2026, selling an estimated $1.17K and leaving 377 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #2449.
US Bancorp first reported a position in ASND in Q4 2016 and has held it in 39 quarters since. The position peaked at $429K in Q3 2025. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- US Bancorp held 377 shares of Ascendis Pharma A/S worth $101K as of Q2 2026.
- US Bancorp sold 5 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.17K.
- Ascendis Pharma A/S made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2449 holding.
- US Bancorp first reported a position in Ascendis Pharma A/S in Q4 2016 and has held it in 39 quarters since.
- US Bancorp's Ascendis Pharma A/S position peaked at $429K in Q3 2025.
- 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.